Keywords: Enzon Pharma, Zhejiang Hisun Pharma, Collaboration, PEG-SN38, China, Licensing
China's Hisun gains access to Enzon technology
Article | 17 May 2012
US biotech firm Enzon Pharmaceuticals (Nasdaq: ENZN) and Chinese drugmaker Zhejiang Hisun Pharmaceuticals (SSE: 600267) have entered into a long-term strategic ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
